K-numberK243937
Device nameAccuro 3S
ApplicantRivanna Medical, Inc.
Product codeIYO
Device classClass II
Decision dateMay 23, 2025
DecisionSubstantially Equivalent
Regulation892.1560
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

The Accuro 3S is a portable diagnostic ultrasound imaging system for use by qualified healthcare professionals in hospitals or medical clinics. It provides B-mode imaging and includes SpineNav-AI machine learning software to assist with musculoskeletal imaging and guidance for procedures like neuraxial anesthesia.

Technological characteristics

The Accuro 3S features a Dual-Array convex transducer probe with two side-by-side PZT-based arrays (64 elements each, 3.5–4.0 MHz center frequency) that compound images into a single sector-scan format, compared to the predicate's mechanically scanned single-element transducer. SpineNav-AI uses deep convolutional neural networks for anatomical segmentation, whereas the predicate's SpineNav3D uses analytical template-matching algorithms. The system includes an integrated battery, touchscreen interface, and DICOM-based archival workflows.

Test standards cited

IEC 60601-1, IEC 60601-1-2, IEC 60601-1-6, IEC 60601-2-37, IEC 62304, IEC 62366-1, IEC 62359, ISO 10993-1, ISO 14971, NEMA UD 2-2004, NEMA PS 3.1–3.20e (DICOM), and AAMI TIR69:2017.

Substantial equivalence argument

Accuro 3S shares the same intended use, user population, and clinical applications (musculoskeletal imaging and neuraxial anesthesia guidance) as the predicate Accuro. Although the transducer geometry differs (Dual-Array versus mechanically scanned), non-clinical testing including acoustic output, safety compliance, and performance validation confirms no new risks. SpineNav-AI, while using machine learning instead of template matching, was validated on 120 test sequences from diverse demographics with per-frame accuracy of 82.1–99.3% and meets established success criteria; this methodology parallels the reference device Venue's cNerve feature. Together these findings support that the technological differences do not affect safety or effectiveness for the intended indications.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →